6533b856fe1ef96bd12b24be

RESEARCH PRODUCT

Immunotherapy with effector cells and IL-2 of lymph node metastases of human squamous-cell carcinoma of the head and neck established in nude mice

Takao SaitoYoshiro KashiiEtsuhide YamamotoShuichi KawashiriKazuaki ChikamatsuTorsten E. ReichertTorsten E. ReichertTheresa L. Whiteside

subject

Cancer ResearchAdoptive cell transferPathologymedicine.medical_specialtyLymphokine-activated killer cellbusiness.industrymedicine.medical_treatmentImmunotherapymedicine.diseaseNatural killer cellMetastasismedicine.anatomical_structureOncologyCervical lymph nodesmedicineCytotoxic T cellbusinessLymph node

description

We have previously reported that immune anti-tumor effector cells, both cytotoxic T lymphocytes (CTLs) and IL-2-activated natural killer (A-NK) cells, are effective at eliminating human head-and-neck cancer (HNC) targets in vitro and in vivo in xenograft models. In this study, these 2 types of human effector cell were compared for the ability to prevent the development of lymph node metastases in a metastasis model of human squamous-cell carcinoma of the head and neck (SCCHN) established in nude mice. A tumor cell line, OSC-19, was injected into the floor of the mouth in nude mice, and the tumor grew progressively and metastasized to cervical lymph nodes by day 21. As effector cells, a human HLA-A2-restricted CTL line recognizing a shared antigen on OSC-19 and human non-MHC-restricted A-NK cells were used. Both types of effector cell mediated high levels of lysis against OSC-19 targets in 4-hr 51Cr-release assays. Administration of human CTLs or A-NK cells and IL-2 to the site of tumor growth in mice with 7-day OSC-19 tumors resulted in significant reduction of the number of lymph node metastases relative to untreated or sham-operated controls or to mice treated with IL-2 without the effector cells. Our results suggest that in a xenograft model of human SCCHN implanted in the oral cavity of nude mice, the development of lymph node metastases can be successfully controlled by adoptive transfer of human SCCHN-specific CTLs or SCCHN-reactive A-NK cells plus IL-2. Int. J. Cancer 82:532–537, 1999. © 1999 Wiley-Liss, Inc.

https://doi.org/10.1002/(sici)1097-0215(19990812)82:4<532::aid-ijc11>3.0.co;2-g